BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in Children With Achondroplasia Transcript
Source: SeekingAlpha
2026-02-12 17:54:19 ET
BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in Children With Achondroplasia February 12, 2026 8:00 AM EST...
Read the full article on Seeking Alpha
For further details see:
BridgeBio Pharma, Inc. (BBIO) Discusses Positive Phase 3 PROPEL 3 Results for Infigratinib in Children With Achondroplasia Transcript
BridgeBio Pharma Inc.
NASDAQ: BBIO
BBIO Trading
-1.29% G/L:
$72.48 Last:
1,329,064 Volume:
$73.16 Open:
BBIO Latest News
BBIO Stock Data
$13,905,867,946
157,635,809
2.34%
155
N/A
Biotechnology & Life Sciences
Healthcare
US
Palo Alto
